Michael Burry Puts His Money Where His Mouth Is For Market Crash Prediction: But Did He Sell Too Soon?
Famed “Big Short” investor Michael Burry has taken an extremely bearish stance during the third quarter of 2022 — but was it too much?
Children’s Place Shares Plummet As Inflation Batters Q2 Earnings
Children’s Place Inc (NASDAQ:PLCE) reported a second-quarter FY22 sales decline of 8% year-on-year to $380.89 million, missing the consensus of $382.42…
Retail Earnings Underway With Target, Walmart Results: Which Of These 5 Retail Stocks Offer Best Dividends?
As we progress through the second quarter earnings season, many top retailers are reporting earnings this week.
Ennis Acquires Assets Of Competitor Gulf Business Forms For Undisclosed Sum
Ennis, Inc. (NYSE:EBF) has acquired certain assets, including customer lists and intellectual property of Gulf Business Forms, in San…
Why This DraftKings Analyst Sees ‘Tactical Opportunity’ In Sports Betting Ahead Of NFL Season
Sports betting and iGaming stocks could be in focus ahead of the National Football League (NFL). One analyst is upgrading a leader in the space and raising the price targets on three stocks.
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle platform.
Fubo Must ‘Cut Cash Burn,’ Former Bull Says Of Sports Streamer Following Investor Day
Webush dropped its bullish stance on Fubotv Inc (NYSE: FUBO) Wednesday.
SFL Shares Gain On Q2 Results, Profit Increases Sequentially
SFL Corporation Ltd (NYSE:SFL) reported second-quarter operating revenue growth of 0.6% Q/Q to $153.3 million, beating the consensus of $149.65…
U.S. Stocks Open Lower; Nasdaq Down 150 Points
U.S. stocks traded lower this morning, with the Nasdaq composite dropping more than 150 points on Wednesday.
AbbVie Calls Off Early-Stage Trial For I-Mab’s CD47-Targeted Blood Cancer Candidate
I-Mab (NASDAQ:IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE:ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with…